Ind-Swift Laboratories Approves Equity Allotment on Warrant Conversion
Ind-Swift Laboratories Ltd · Others · 09 Oct 2026, 12:10 am
Ind-Swift Laboratories Approves Equity Allotment on Warrant Conversion Ind-Swift Laboratories Limited's Preferential Issue Committee approved the allotment of 14,00,000 equity shares (face value ₹10 each) on 8th Oct'26 upon conversion of fully convertible warrants issued at ₹196 each to promoter entity Essix Biosciences Limited. The conversion followed receipt of the balance 75% consideration of ₹147 per warrant, aggregating ₹20.58 Cr. Consequently, the company's paid-up equity share capital increased from ₹86.71 Cr (8,67,11,558 shares) to ₹86.96 Cr (8,69,61,558 shares).
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. · 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. · 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 · 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants · 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants · 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... · 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 · 30 Oct 2026
- Please refer attached pdf · 30 Oct 2026
